Learning objectives
After this module you should be able to:
- Explain why fibrosis stage, rather than steatosis or ALT, predicts outcomes in MASLD.
- Select patients for fibrosis assessment and apply the two-step pathway (FIB-4, then elastography or ELF).
- Interpret FIB-4, NFS, liver stiffness and ELF results, including grey-zone values and common pitfalls.
- Decide on follow-up interval and referral, and recognise the limits of non-invasive tests.
Boxed recommendations are paraphrased from the EASL–EASD–EASO 2024 guideline, with its grades: evidence level from 1 (strongest) to 5; recommendation strong, weak or open; consensus is the panel's agreement (strong means at least 95%).
1Why fibrosis is the target
Most people with MASLD will never develop liver complications. The task is to find the minority who will. Across long-term biopsy cohorts, fibrosis stage is the histological feature that best predicts death and liver events; steatosis grade, ballooning and inflammation add little once fibrosis is known [1].
A meta-analysis of 1,495 patients showed that all-cause mortality increases at every stage, and liver-related mortality rises exponentially from F2 onwards [2]. In the prospective NASH CRN cohort of 1,773 adults, deaths rose from 0.32 per 100 person-years at F0–F2 to 0.89 at F3 and 1.76 at F4, and decompensation events clustered in F3–F4 [3].
In practice, this means that the clinical question is not "does this patient have fatty liver?" but "does this patient have advanced fibrosis (F3–F4), or significant fibrosis (F2) that could progress?". Liver enzymes cannot answer it: ALT is often normal in advanced disease.
2Whom to assess
An incidental finding of steatosis should lead to a search for its cause and a test for advanced fibrosis. [4]
Population-wide screening for steatotic liver disease is not advised. [4]
Case-finding for MASLD with fibrosis can be considered in people with cardiometabolic risk factors, abnormal liver enzymes or steatosis on imaging. [4]
The highest-yield groups are adults with type 2 diabetes, obesity with at least one other metabolic risk factor, persistently raised aminotransferases, or steatosis found on imaging [4,5]. In the Middle East, where about 7 in 10 people with type 2 diabetes have MASLD, diabetes clinics are the natural starting point [6].
3Step 1: blood-based scores
Use non-invasive scores, not ALT and AST alone, to detect fibrosis. [4]
Use a multi-step approach: a non-patented blood score such as FIB-4 first, then elastography if fibrosis is still suspected or the patient is high risk. [4]
FIB-4 needs only age, AST, ALT and platelets, so it can be calculated for every patient in primary care. NFS adds BMI, glycaemic status and albumin. In an individual patient data meta-analysis of 5,735 biopsied patients, the AUROC for advanced fibrosis was 0.76 for FIB-4 and 0.73 for NFS [7]. Their strength is a high negative predictive value: a low score reliably rules out advanced fibrosis.
| Score | Formula | Rule out | Rule in |
|---|---|---|---|
| FIB-4 | (age × AST) ÷ (platelets × √ALT) | <1.3; <2.0 if age ≥65 | ≥2.67 |
| NFS | −1.675 + 0.037×age + 0.094×BMI + 1.13×IFG/diabetes + 0.99×AST/ALT − 0.013×platelets − 0.66×albumin (g/dL) | <−1.455; <0.12 if age ≥65 | >0.676 |
Two age limits matter. Under 35, both scores perform poorly and should not be relied upon; go directly to elastography if concerned. At 65 or over, use the higher rule-out cut-offs to avoid over-referral [8]. You can calculate both scores in the Physician Portal.
4Step 2: elastography or ELF
Blood scores and elastography should be used to exclude advanced fibrosis; elastography is better suited to confirm it. [4]
Collagen-turnover blood tests such as ELF can be used instead of imaging to identify advanced fibrosis. [4]
Vibration-controlled transient elastography (VCTE, FibroScan) measures liver stiffness in kPa. In a prospective study of 450 patients, liver stiffness identified F≥3 with an AUROC of 0.80 and cirrhosis with 0.89 [9]. In the pooled IPD analysis its AUROC for advanced fibrosis was 0.85, clearly better than blood scores [7]. The guideline cut-offs are below 8 kPa (low risk), 8–12 kPa (grey zone) and 12 kPa or more (high risk) [4,5].
| Test | Low risk | High risk | Practical notes |
|---|---|---|---|
| VCTE liver stiffness | <8 kPa | ≥12 kPa | Fast 3 h; XL probe if obese; valid if IQR/median ≤30%; ≥15 kPa suggests compensated advanced chronic liver disease |
| ELF | <7.7 | ≥9.8 | Laboratory test; useful where elastography is unavailable; rises with age and other fibrotic diseases |
| MR elastography | centre-specific | centre-specific | Most accurate imaging test; costly and less available |
5The pathway in practice
Care pathways that apply blood scores and imaging in sequence can be adopted, since most adults with MASLD are seen outside hepatology. [4]
Sequencing works. In the IPD meta-analysis, FIB-4 followed by liver stiffness classified most patients, with about a third left indeterminate [7]. In a UK primary care pathway using FIB-4 then ELF, five times more cases of advanced fibrosis and cirrhosis were detected, while unnecessary referrals to hospital fell by 81% [10].
6Limits of non-invasive tests
Non-invasive tests cannot assess ballooning or lobular inflammation. [4]
Most patients do not need a liver biopsy, but biopsy remains the only way to diagnose steatohepatitis with certainty and can rule out other liver diseases. [4]
Consider biopsy when non-invasive results disagree, when another or a second liver disease is suspected, or within a clinical trial. Remember that a low score in a patient with clinical, laboratory or imaging signs of cirrhosis does not exclude it.
7Follow-up over time
Non-invasive tests may be repeated in an individual to follow fibrosis progression, but tell you little about treatment response. [4]
Non-invasive tests also predict outcomes: over a median of almost five years, liver stiffness, FIB-4 and NFS predicted liver events about as well as biopsy [11]. Repeat a low-risk FIB-4 every 1–3 years (EASL); AASLD suggests every 1–2 years with diabetes or two or more metabolic risk factors, and every 2–3 years otherwise [4,5]. Patients in the grey zone need a repeat second-line test in about a year or specialist review.
8Our region
In a survey of 584 physicians from Saudi Arabia, Egypt and Türkiye, 81–84% of specialists but only 38–51% of non-specialists reported following society guidelines [12]. With MASLD affecting about 4 in 10 adults in the region [6], the biggest gain will come from making FIB-4 routine in primary care and diabetes clinics, with clear access to elastography.
9Clinical case
A 52-year-old man with type 2 diabetes
- Presentation
- Seen in a diabetes clinic in Riyadh. BMI 33 kg/m², HbA1c 7.8%, on metformin. Ultrasound shows a bright liver. AST 42 U/L, ALT 48 U/L, platelets 210 ×10⁹/L. He drinks no alcohol; hepatitis B and C serology are negative.
- Step 1
- FIB-4 = (52 × 42) ÷ (210 × √48) = 1.50. This is indeterminate (1.3–2.67), so a second-line test is needed.
- Step 2
- VCTE (XL probe, fasting): liver stiffness 10.8 kPa, IQR/median 18%. This is in the grey zone (8–12 kPa).
- Next step
- ELF is 10.1 (≥9.8, high risk). Together the results suggest at least significant fibrosis, probably F2–F3, without cirrhosis. He is referred to hepatology.
- Teaching points
- A normal-looking ALT and an "only fatty" ultrasound did not exclude significant fibrosis. If the hepatologist confirms at-risk MASH, semaglutide 2.4 mg could treat his obesity, diabetes and liver together where it is approved (AASLD 2025 guidance), alongside lifestyle change and a statin. Note that EASL 2024, written before the semaglutide phase 3 trial, did not yet recommend GLP-1 drugs as liver treatment. See Module 2.
10Test yourself
Choose an answer to see the explanation. Nothing is recorded.
1. A 70-year-old woman with MASLD has FIB-4 of 1.8. What is the best interpretation?
From age 65, the rule-out cut-off for FIB-4 is 2.0, which restores specificity without losing much sensitivity.
2. Which histological feature best predicts long-term outcomes in MASLD?
In long-term biopsy cohorts, fibrosis stage was the only histological feature independently linked to death, transplant and liver events.
3. FIB-4 is 1.6 and liver stiffness is 9.5 kPa. What next?
8–12 kPa is the grey zone. A further test or specialist review is needed before deciding on treatment or reassurance.
4. Which of these does NOT falsely raise liver stiffness?
The XL probe is the correct probe for obese patients. Food, acute hepatitis and congestion all raise stiffness.
5. Why is FIB-4 used as the first step rather than elastography?
FIB-4 is less accurate than elastography but costs almost nothing and has a high negative predictive value, so it filters out most low-risk patients.
11Key messages
- Fibrosis stage, not steatosis or ALT, drives prognosis in MASLD.
- Assess people with diabetes, obesity plus a metabolic risk factor, raised enzymes or steatosis on imaging. Do not screen everyone.
- FIB-4 first (<1.3, or <2.0 at age 65+, is low risk), then elastography (<8 low, 8–12 grey, ≥12 kPa high) or ELF.
- Do not use FIB-4 or NFS under age 35; beware of false-high stiffness.
- Repeat low-risk tests every 1–3 years; refer high-risk patients.
References
- Angulo P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with NAFLD. Gastroenterology 2015;149(2):389–97. doi:10.1053/j.gastro.2015.04.043
- Dulai PS, et al. Increased risk of mortality by fibrosis stage in NAFLD: systematic review and meta-analysis. Hepatology 2017;65(5):1557–65. doi:10.1002/hep.29085
- Sanyal AJ, et al. Prospective study of outcomes in adults with NAFLD. N Engl J Med 2021;385(17):1559–69. doi:10.1056/NEJMoa2029349
- EASL–EASD–EASO Clinical Practice Guidelines on the management of MASLD. J Hepatol 2024;81:492–542. doi:10.1016/j.jhep.2024.04.031
- Rinella ME, et al. AASLD Practice Guidance on the clinical assessment and management of NAFLD. Hepatology 2023;77:1797–835. doi:10.1097/HEP.0000000000000323
- Younossi ZM, et al. Prevalence of MASLD in the Middle East and North Africa. Liver Int 2024;44(4):1061–70. doi:10.1111/liv.15852
- Mózes FE, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut 2022;71(5):1006–19. doi:10.1136/gutjnl-2021-324243
- McPherson S, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2017;112:740–51. doi:10.1038/ajg.2016.453
- Eddowes PJ, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in NAFLD. Gastroenterology 2019;156(6):1717–30. doi:10.1053/j.gastro.2019.01.042
- Srivastava A, et al. Prospective evaluation of a primary care referral pathway for patients with NAFLD. J Hepatol 2019;71(2):371–8. doi:10.1016/j.jhep.2019.03.033
- Mózes FE, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in NAFLD: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol 2023;8(8):704–13. doi:10.1016/S2468-1253(23)00141-3
- Alqahtani SA, et al. Knowledge about MASLD among medical professionals from countries in the MENA region. Ann Hepatol 2025;30(1):101569. doi:10.1016/j.aohep.2024.101569
How to cite this module
Desoky M. Assessing liver fibrosis in MASLD. Metabolic Liver Academy, version 1.0. Updated 2026-10-03. Available from: https://drmahmouddesoky.github.io/metabolic-liver-academy/modules/fibrosis-assessment.html
For education only. This module summarises published evidence and guidelines; it does not replace clinical judgement, full guidelines or local drug labels. It is not accredited for CME credit. Disclaimer.